Loading ...
Monday, February 24, 2025
High Beta, High Alpha Play on Futuristic Themes
By Century Financial in 'Investment Insights'
.jpg)
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Disclaimer
These stocks are high-beta investments tied to futuristic, high-growth themes. While they offer strong return potential, they are also highly volatile and more sensitive to market fluctuations. With a portfolio beta of 2.43, in a market downturn, the prices of the stocks may fall more sharply than the broader market or benchmark indices. Investors should assess their risk tolerance and investment horizon, as these stocks can see significant short-term price swings and potential capital losses. This portfolio is suitable for investors with a high-risk appetite.
Analyst rating
Buy
21
Hold
7
Sell
0
| Name | Intellia Therapeutics Inc |
|---|---|
| ICB Subsector Name | Biotechnology |
| Ticker | NTLA |
| Last Price | $11.53 |
| 52-Week Low | $8.96 |
| 52-Week High | $34.87 |
| Market Capitalization ($ Billion) | $1.09 |
| Analyst Target Price | $49.00 |
| Beta | 3.05 |
| Shares Outstanding (Mn) | 101.85 |
| Avg 30 Day Volume (Mn) | 2.98 |
| Forward P/S | 23.77 |
| Forward EV/Sales | 5.38 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage genome editing company that develops curative therapeutics using the CRISPR/Cas9 system. This system transforms medicine by producing therapeutics that permanently edit and correct disease-associated genes in the human body with a single treatment course. It also creates engineered cells that can treat oncological and immunological diseases.
NTLA has shown promising results in its clinical trials, particularly with NTLA-2002 for HAE. HAE, better known as hereditary angioedema, is a genetic disorder that causes unpredictable and debilitating swelling episodes. The current treatments for HAE focus on frequent injections or infusions to prevent attacks, which can be burdensome for patients. NTLA’s NTLA-2002 provides a one-time potentially curative solution by silencing the “KLKB1 gene”, thereby resulting in the reduction of the kallikrein protein levels, which are responsible for triggering HAE attacks. It must be noted that NTLA-2002 is a single-dose therapy that could replace lifelong frequent injections and infusions; hence, if widely commercialized, NTLA could capture a significant share of this HAE market. In October, NTLA presented positive Phase 2 results. According to the results, deep attack reduction was observed—a single dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectively. According to a study, the market size of HAE is expected to touch $5.36 billion by 2031, presenting a significant opportunity for NTLA.
Another impressive NTLA product is NTLA-2001, a drug that addresses Transthyretin amyloidosis (ATTR). ATTR causes the build-up of the protein transthyretin in the heart, which leads to nerve damage and, eventually, heart failure. If it gets commercialized, NTLA could target an addressable market as large as 550,000 people with ATTR and its various subtypes worldwide, and the market for interventions for the condition could be worth more than $11 billion by 2029. Capturing a mere 5% of the market could dramatically increase NTLA's revenue.
Of course, there is a risk that NTLA will not easily commercialize the program. Given the gravity of making permanent changes to patients' genomes, FDA regulators will scrutinize its safety data very carefully. However, for aggressive investors looking for a beaten-down stock in the biotech sector, NTLA is an attractive addition.
Analyst rating
Buy
7
Hold
3
Sell
0
| Name | TransMedics Group Inc |
|---|---|
| ICB Subsector Name | Health Care Equipment & Supplies |
| Ticker | TMDX |
| Last Price | $75.02 |
| 52-Week Low | $55.00 |
| 52-Week High | $177.37 |
| Market Capitalization ($ Billion) | $2.42 |
| Analyst Target Price | $102.38 |
| Beta | 1.82 |
| Shares Outstanding (Mn) | 33.56 |
| Avg 30 Day Volume (Mn) | 2.30 |
| Forward P/S | 4.94 |
| Forward EV/Sales | 5.33 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
TransMedics Group Inc
TransMedics Group, Inc. (TMDX) is an American MedTech company addressing the growing need for healthier organ transplantation transplants. TMDX developed the Organ Care System (OCS) platform, a technology for preserving organs and treating end-stage heart, lung, and liver failure. The OCS system provides a superior transplant outcome than the traditional ice storage process used historically in organ donations. By keeping donated hearts beating, lungs breathing, and liver functioning, TMDX's OCS adds valuable hours of transport time for organs to reach their recipients.
It must be noted that the OCS is the first and only commercialized Food and Drug Administration (FDA) approved medical device for heart, lung, and liver transplantation in the US to extend organ preservation time. Given its one-of-a-kind nature, the firm has had a tremendous financial performance.
In Q3 2024, the firm's revenue grew 64% YoY, reaching $108.8 million. Net income also witnessed a similar trend, rising to $4.2 million from a net loss of $25.4 million in Q3 2023. However, gross margins declined to 56% in Q3 2024 from 61% in Q3 2023, mainly owing to investments in the National OCS Program network to prepare for future growth. Looking at transplant volumes, according to the firm's projections, TMDX is estimated to have aided 3,600 transplants in 2024 and is targeting more than 10,000 annually by 2028.
Apart from these, the company has also begun to develop the Kidney OCS, which is expected to start trials in 2027 and potentially launch in 2029. To understand the potential here, there are 25,000 kidney transplants in the US each year, compared to only 17,000 transplants done annually for hearts, lungs, and livers combined!! In the long run, the firm has also begun exploring non-US markets. For understanding, there are over 40,000 transplants outside the US annually; TMDX could see decades of growth if it succeeds in international markets.
In conclusion, TMDX is buoyed for a surge as it is a first mover in the industry, and despite being in hyper-growth mode and heavily investing in logistics with a newly assembled fleet of 18 planes and a dedicated command centre to support its logistical network, TMDX is profitable and also has positive cash from operations.
Analyst rating
Buy
5
Hold
3
Sell
0
| Name | IonQ Inc |
|---|---|
| ICB Subsector Name | Technology Hardware & Storage |
| Ticker | IONQ |
| Last Price | $33.94 |
| 52-Week Low | $6.22 |
| 52-Week High | $54.74 |
| Market Capitalization ($ Billion) | $8.11 |
| Analyst Target Price | $44.33 |
| Beta | 3.90 |
| Shares Outstanding (Mn) | 216.39 |
| Avg 30 Day Volume (Mn) | 28.86 |
| Forward P/S | 118.46 |
| Forward EV/Sales | 113.38 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
IonQ Inc
IonQ, Inc. stands at the forefront of quantum computing and networking, offering cutting-edge systems designed to tackle the most challenging commercial and research problems globally. Quantum computing can solve complex problems that traditional computers cannot, using unique particle properties to process a lot of information at once. IonQ’s current generation of computers, the IonQ Forte and IonQ Forte Enterprise stand at the forefront of this revolution, boasting 36 algorithmic qubits.
The company recently won the largest quantum contract in 2024 from the United States Air Force Research Lab, amounting to $54.5 million, adding to the $63.5 million in third-quarter bookings. This contract was further expanded by another $21.1 million in January. In the latest earnings report, the company showcased a robust $383 million quarter-ending cash balance.
The use of qubits is what differentiates quantum computers from regular computers. It is generally used to describe the probability of information between 0 and 1, which means it can store infinitely higher amounts of data. However, it can also multiply the chances of an error, and a quantum computer needs to solve this issue to become commercial. IonQ expects to achieve 99.95% fidelity in 2026, showcasing how its products are performing. This is attracting contracts for the company, which are essential to continue developing the technology. In line with the same, the total addressable market for IonQ is expected to reach $65 billion, with the company expecting profitability and revenues exceeding $1 billion by 2030.
IonQ had recently acquired quantum networking company Qubitekk in 3Q24. The company’s management believes quantum networking will be the first positive cash flow product segment in its business. Furthermore, the company announced a collaboration with AstraZeneca to leverage world-class scientists and quantum experts to develop applications. Due to the trial-and-error process involved in developing drugs, the company is seeing a high interest from the pharmaceutical industry as quantum computers can process machine learning with much less data compared to traditional computers.
Analyst rating
Buy
12
Hold
9
Sell
3
| Name | NU Holdings Ltd |
|---|---|
| ICB Subsector Name | Transaction Processing Services |
| Ticker | NU |
| Last Price | $13.54 |
| 52-Week Low | $9.67 |
| 52-Week High | $16.15 |
| Market Capitalization ($ Billion) | $65.08 |
| Analyst Target Price | $15.00 |
| Beta | 1.30 |
| Shares Outstanding (Mn) | 3755.13 |
| Avg 30 Day Volume (Mn) | 35.52 |
| Forward P/S | 4.55 |
| Forward EV/Sales | 4.16 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
Nu Holdings
Nu Holdings Ltd. is a leader in the Latin American digital banking sector based in Brazil. The company provides various services like credit and prepaid cards, crypto trading tools, investment and insurance platforms, and even an e-commerce option. The company has been attracting a lot of attention backed by its robust growth trend in adding members along with recording higher profits year-over-year (YoY).
According to the company’s latest quarterly earnings report, revenues were up 56% YoY, touching a record $2.9 billion, indicating the consistently expanding user base. Gross profit stood at $1.348 billion, marking a 67% YoY growth, while Net income was reported at $553.4 million, up from $303 million a year ago. Net interest income showed a 63% YoY growth, reaching $1.7 billion for the quarter, on a net interest margin of 18.4% for the quarter. The high levels of profitability were achieved despite the company holding significant excess cash of $2.4 billion, potentially for leveraging investments in future products and geographic expansion.
The company has crossed 100 million customers in Brazil, growing users by an average of 1.1 million monthly. This represented about 56% of the country’s adult population, which in itself was the largest in Latin America. Internationally, the company added 1.2 million customers in Mexico, surpassing a total of 8.9 million, while Colombia saw customers beyond 2 million by the quarter end. These growth trends validate the strategy of launching high-rate savings accounts in these markets while also indicating a long runway for future expansion.
Nu is utilizing a strategy of targeting Brazil’s mass consumers along with an affluent client base, on the back of its easy-to-use financial app leading to efficient digital banking operations. About 60% of active members in the country use Nu as their primary bank account, and activity rate for the app has gone up to 83.6% from 82.8% a year ago. Adding to the tailwinds, the company has also increased its average revenue per active user from $10 to $11 YoY, by generating growth from existing members, along with expanding its platform to include bank accounts, loan products, and investing tools.
Analyst rating
Buy
14
Hold
1
Sell
0
| Name | EHang Holdings Ltd |
|---|---|
| ICB Subsector Name | Aerospace & Defense |
| Ticker | EH |
| Last Price | $25.34 |
| 52-Week Low | $10.01 |
| 52-Week High | $29.76 |
| Market Capitalization ($ Billion) | $1.62 |
| Analyst Target Price | $23.10 |
| Beta | 2.84 |
| Shares Outstanding (Mn) | 43.99 |
| Avg 30 Day Volume (Mn) | 2.23 |
| Forward P/S | 16.67 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
EHang Holdings
Nu Holdings Ltd. is a leader in the Latin American digital banking sector based in Brazil. The company provides various services like credit and prepaid cards, crypto trading tools, investment and insurance platforms, and even an e-commerce option. The company has been attracting a lot of attention backed by its robust growth trend in adding members along with recording higher profits year-over-year (YoY).
According to the company’s latest quarterly earnings report, revenues were up 56% YoY, touching a record $2.9 billion, indicating the consistently expanding user base. Gross profit stood at $1.348 billion, marking a 67% YoY growth, while Net income was reported at $553.4 million, up from $303 million a year ago. Net interest income showed a 63% YoY growth, reaching $1.7 billion for the quarter, on a net interest margin of 18.4% for the quarter. The high levels of profitability were achieved despite the company holding significant excess cash of $2.4 billion, potentially for leveraging investments in future products and geographic expansion.
The company has crossed 100 million customers in Brazil, growing users by an average of 1.1 million monthly. This represented about 56% of the country’s adult population, which in itself was the largest in Latin America. Internationally, the company added 1.2 million customers in Mexico, surpassing a total of 8.9 million, while Colombia saw customers beyond 2 million by the quarter end. These growth trends validate the strategy of launching high-rate savings accounts in these markets while also indicating a long runway for future expansion.
Nu is utilizing a strategy of targeting Brazil’s mass consumers along with an affluent client base, on the back of its easy-to-use financial app leading to efficient digital banking operations. About 60% of active members in the country use Nu as their primary bank account, and activity rate for the app has gone up to 83.6% from 82.8% a year ago. Adding to the tailwinds, the company has also increased its average revenue per active user from $10 to $11 YoY, by generating growth from existing members, along with expanding its platform to include bank accounts, loan products, and investing tools.
Analyst rating
Buy
7
Hold
2
Sell
0
| Name | Archer Aviation Inc |
|---|---|
| ICB Subsector Name | Aerospace & Defense |
| Ticker | ACHR |
| Last Price | $10.67 |
| 52-Week Low | $2.82 |
| 52-Week High | $12.48 |
| Market Capitalization ($ Billion) | $4.71 |
| Analyst Target Price | $11.22 |
| Beta | 2.83 |
| Shares Outstanding (Mn) | 419.29 |
| Avg 30 Day Volume (Mn) | 31.42 |
| Forward P/S | - |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
Archer Aviation Inc
Archer Aviation Inc. is designing and developing electric vertical take-off and landing (“eVTOL”) aircraft for use in urban air mobility (“UAM”) networks. Archer intends to operate two complementary lines of business: sale of the aircraft to other operators (“Archer Direct”) and a direct-to-consumer aerial ride-share service (“Archer UAM”) with the goal to reach commercialization as early as 2025.
The company reported strong Q324 results with over $500M of cash and cash equivalents position as strong as it has been over the last 18 months. Archer has also signed an MOU with Stellantis for up to ~$400 million of additional capital to help scale the manufacturing of its Midnight aircraft. The company established a consortium led by the Abu Dhabi Investment Office (ADIO) to launch commercial air taxi services in the UAE as early as Q425 and signed a partnership with Japan Airlines and Sumitomo Corporation’s joint venture, Soracle, with a planned order of up to $500 million of Midnight aircraft, bringing Archer’s indicative order book to $6 billion+.
Archer raised $301.75 million at $8.50 per share, boosting total liquidity to about $1 billion. With strong backing from BlackRock-managed funds, Archer now has one of the strongest balance sheets among public eVTOL firms. At current spending levels, this funding secures about two years of operations.
Archer Aviation received FAA certification to launch its pilot training academy. This certification is granted to a flight school by the FAA, signifying that it is a formally recognized and regulated institution for pilot training. With this certificate, Archer can now train and qualify pilots as part of its newly launched training academy, with plans to build a pipeline of pilots in preparation for its planned commercial air taxi services with its Midnight aircraft.
Further the company has partnered exclusively with Anduril to develop a hybrid VTOL military aircraft, aiming for a major U.S. Department of Defense contract. While Archer already delivered an aircraft under a $142 million Air Force contract, this new program could be worth billions, driving significant growth.
Archer uses a traditional aerospace manufacturing approach with suppliers and has a strong partnership with Stellantis, which should help them scale up production smoothly and navigate regulations more easily. Their revenue model leans heavily on selling aircraft to big manufacturers, potentially making them profitable earlier than competitors.
The investment case for ACHR remains strong due to their legacy industry supplier-based manufacturing model, partnership with Stellantis and Anduril, and FAA air taxi regulation advancements.
Analyst rating
Buy
11
Hold
2
Sell
0
| Name | Enovix Corp |
|---|---|
| ICB Subsector Name | Electrical Equipment |
| Ticker | ENVX |
| Last Price | $11.16 |
| 52-Week Low | $5.70 |
| 52-Week High | $18.68 |
| Market Capitalization ($ Billion) | $2.16 |
| Analyst Target Price | $28.38 |
| Beta | 3.13 |
| Shares Outstanding (Mn) | 188.39 |
| Avg 30 Day Volume (Mn) | 6.80 |
| Forward P/S | 70.91 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
.png)
Enovix Corp
Enovix is a lithium-ion battery company aiming to revolutionize the industry with its cutting-edge technology. Unlike traditional lithium-ion batteries that use graphite anodes, Enovix has developed batteries with silicon anodes, offering higher energy density and improved safety. Simply put, its batteries last longer and perform better, making them ideal for smartphones, IoT devices, and emerging technologies.
Though still in the early stages of growth, Enovix has started generating revenue, bringing in $6.2 million in 2022. In 2023, revenue climbed 23% to $7.6 million, and in 2024, it's projected to skyrocket by 190% to $22.2 million. Financially, the company has $200 million in cash and $197 million in debt, which isn’t due for another three years giving it the flexibility to focus entirely on scaling production.
A key part of this growth strategy is its new factory in Malaysia. Enovix completed Site Acceptance Testing (SAT) for its high-volume manufacturing line at Fab-2 in December 2024, clearing one of the final hurdles before mass production begins in 2025. At the same time, the company is working on a major partnership with a Fortune 50 company to bring its batteries to market. It also secured a prepaid purchase order from a “Silicon Valley-based global technology leader” for a battery designed for Mixed Reality (MR) wearables. This win not only validates Enovix’s technology but could also open doors for more deals in the MR/AR/VR space, where battery life is a top priority.
The demand for better batteries is rising, and Enovix is positioning itself as a frontrunner. The critical next step is improving its production yields to 90%. Once achieved, the company will be ready to scale, secure big-name customers, and transition from a startup into a high-growth powerhouse.
Analyst rating
Buy
10
Hold
7
Sell
1
| Name | Symbotic Inc |
|---|---|
| ICB Subsector Name | Machinery |
| Ticker | SYM |
| Last Price | $27.81 |
| 52-Week Low | $17.11 |
| 52-Week High | $50.41 |
| Market Capitalization ($ Billion) | $15.92 |
| Analyst Target Price | $34.20 |
| Beta | 2.54 |
| Shares Outstanding (Mn) | 107.70 |
| Avg 30 Day Volume (Mn) | 2.57 |
| Forward P/S | 6.47 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
Symbotic Inc
Symbotic is revolutionising warehouse automation with its AI-powered robotics, helping major retailer players like Walmart streamline their supply chains. Its fully autonomous systems are already deeply integrated into Walmart’s logistics network, and now, the two companies are strengthening their partnership.
Walmart is investing $520 million to support Symbotic’s development of advanced automation for hundreds of its Accelerated Pickup and Delivery Centers (APDs). If performance targets are met, Walmart has committed to deploying Symbotic’s systems in 400 APDs over the next several years. On top of this, Symbotic is acquiring Walmart’s advanced systems and robotics business for $200 million, with up to $350 million in additional payments. This deal enhances Symbotic’s automation expertise, adds over $5 billion to its backlog, and opens a new market in micro-fulfillment. For Walmart, it simplifies operations while keeping access to top-tier robotics.
Financially, Symbotic is on a strong trajectory. It reported Q4 2024 revenue of $576 million, up 44% year over year, surpassing analyst expectations by a large $106 million. Nearly most of this, or 95%, came from its Systems segment, which includes design, assembly, and software configuration. Full-year revenue climbed 51% to $1.7 billion, reflecting the growing demand for its automation solutions. Gross profit margin in the previous two financial quarters clocked in at 17% and 16%, rising from the previous 11% in Q3 2024 & 8% in Q2 2024. With $900 million in cash and just $24 million in debt, Symbotic has the flexibility to scale rapidly. As AI-driven automation reshapes logistics, the company is well-positioned to lead the transformation, turning warehouses into intelligent, autonomous hubs that define the future of retail logistics.
Analyst rating
Buy
9
Hold
2
Sell
0
| Name | PROCEPT BioRobotics Corp |
|---|---|
| ICB Subsector Name | Health Care Equipment & Supplies |
| Ticker | PRCT |
| Last Price | $66.92 |
| 52-Week Low | $45.20 |
| 52-Week High | $103.81 |
| Market Capitalization ($ Billion) | $3.68 |
| Analyst Target Price | $106.40 |
| Beta | 1.47 |
| Shares Outstanding (Mn) | 54.39 |
| Avg 30 Day Volume (Mn) | 0.85 |
| Forward P/S | 12.74 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corporation is a Silicon Valley-based surgical robotics company that is revolutionizing the field of urology with its innovative solutions. The company's flagship product, the AquaBeam Robotic System, is an advanced, image-guided surgical robot designed for minimally invasive urologic surgery, initially targeting benign prostatic hyperplasia (BPH). The AquaBeam Robotic System autonomously removes tissue to treat BPH effectively and safely, allowing for consistent results. The company's commitment to improving patient outcomes is supported by a substantial body of clinical evidence, including nine studies and over 150 peer-reviewed publications.
The recent financial results showcase strong revenue growth, improved gross margins, and a robust financial foundation, positioning the company for long-term success. The 66% revenue growth in Q3 2024, driven by increased handpiece and system sales, is a testament to the growing demand for the AquaBeam Robotic System and the company's ability to execute on its strategy. The record gross margin of 63.2% is an indication of operational efficiency and the company's focus on cost reduction. Furthermore, the growth in international revenue, particularly in the United Kingdom, highlights the company's potential for expansion beyond the US market. The launch of the new Hydro robotic system, which features AI capabilities and an improved user interface, has received positive feedback and is expected to drive further growth.
Additionally, the FDA's breakthrough device designation for a new clinical study on prostate cancer presents a significant opportunity for the company to expand its market and further establish itself as a leader in surgical robotics. Despite a net loss, the company's financial foundation, including its cash and short-term investments, positions it well for future growth and development.
PROCEPT BioRobotics' strong financial performance, innovative products, and clinical evidence support a positive outlook for the company, making it an attractive investment opportunity in the life sciences sector. Poised for continued growth and success in the surgical robotics industry, particularly in the field of urology. The company's flagship product, the AquaBeam Robotic System, has demonstrated significant clinical benefits and has garnered substantial attention and acclaim in the medical community.
Analyst rating
Buy
19
Hold
0
Sell
1
| Name | Natera Inc |
|---|---|
| ICB Subsector Name | Biotechnology |
| Ticker | NTRA |
| Last Price | $169.38 |
| 52-Week Low | $68.03 |
| 52-Week High | $183.00 |
| Market Capitalization ($ Billion) | $22.89 |
| Analyst Target Price | $193.12 |
| Beta | 1.46 |
| Shares Outstanding (Mn) | 132.02 |
| Avg 30 Day Volume (Mn) | 1.34 |
| Forward P/S | 12.87 |
Source: Bloomberg
Date: 19th February 2025
*Last Price: 18th February 2025
Price Chart
Natera Inc
Natera Inc., a global leader in cell-free DNA and genetic testing, recently published its financial report for the third quarter of 2024.
The company presents a compelling narrative of sustained growth, operational efficiency, and strategic progress, underscoring the company's position as a global leader in cell-free DNA and genetic testing. The standout feature Natera is the remarkable 63.9% year-over-year revenue growth to $439.8 million, driven primarily by a 63.9% increase in revenues, which not only demonstrates the company's ability to scale its operations but also highlights the growing demand for its innovative products and services.
Furthermore, the expansion of gross margin to 61.8% from 45.1% in the same period last year is a testament to Natera's focus on operational efficiency and cost reduction, as well as its ability to negotiate favorable pricing with customers. The company's strong performance is also reflected in its ability to process a record 775,800 tests, a 23.9% increase from the same period last year, with oncology tests, in particular, showing a 54.4% increase, underscoring the growing importance of Natera's SignateraTM product in the oncology space.
Moreover, the company's achieved a positive cash flow of $35.5 million and its decision to raise annual guidance for 2024, expecting total revenue of $1.61 billion to $1.64 billion and a gross margin of 58% to 61%, further reinforces the notion that Natera is well-positioned for continued growth and expansion.
Natera's Q3 report suggests that the company is executing well on its strategy, and its strong financial performance, coupled with its innovative products and services, position it for long-term success in the life sciences sector.
Risks and Assumptions related to Back-tested trading strategies
Disclaimer:Century Financial Consultancy LLC (CFC) is duly licensed and regulated by the Securities and Commodities Authority of UAE (SCA) under license numbers 20200000028, 20200000081 and 301044 to practice the activities of Trading broker in the international markets, Trading broker of the OTC derivatives and currencies in the spot market, Introduction, Financial Consultation and Financial Analysis, and Promotion. CFC is a Limited Liability Company incorporated under the laws of UAE and registered with the Department of Economic Development of Dubai (registration number 768189). CFC has its registered office at 601, Level 6, Building no. 4, Emaar Square, Downtown, Dubai, UAE, PO Box 65777.
PLEASE READ THE FOLLOWING TERMS AND CONDITIONS OF ACCESS FOR THE PUBLICATION BEFORE THE USE THEREOF.
Please carefully read the terms and conditions before using the Publication (which means and includes this document/flyer, charts, diagrams, illustrations, images, and all of its contents) ("Publication"). By accessing and continuing to use the Publication, you acknowledge and accept the terms and conditions outlined in this Disclaimer ("Disclaimer"). CFC holds the right to modify or update the Publication and the Disclaimer at any time without any prior notice. Your access and usage of the Publication post the modifications or updates to the Disclaimer will constitute your agreement to abide by the revised terms and conditions. If you do not agree with the contents of this Disclaimer please refrain from using the Publication. Any terms and conditions you propose that may contradict this Disclaimer are liable to be rejected by CFC and shall be considered null and void.
This Publication is a marketing material. It has not been prepared in accordance with legal requirements intended to promote the independence of investment research and, therefore, is a straightforward marketing communication. This Publication's opinions, news, research, analysis, prices, and other information comprise a general market commentary and do not represent the opinion or advice of CFC or any form of personalized or investment advice. Accordingly, CFC is not liable for any loss or damage, including but not limited to any loss of profit, that may arise directly or indirectly from using or relying on this Publication.
The information in this Publication cannot disclose everything about the nature and risks of the abovementioned data/information. Therefore, this is not an exhaustive list of the risks involved. Please refer to our website for the complete Risk Disclosure Statement.
Charts, graphs, tables, calculations of profit and loss, leverage, scenario analysis, other numbers and calculations and related data or information provided in this Publication are intended for illustrative purposes only. The information contained in this Publication is prepared as of a particular date and time and will not reflect subsequent changes in the market or any other factors relevant to their determination. All statements as to future matters are not guaranteed to be accurate. CFC disclaims any obligation to amend or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this Publication or to reflect the occurrence of unanticipated events. The Publication may contain forward-looking statements and projections based on current market conditions and an assessment of future trends. Actual results may differ materially from those projected. CFC does not guarantee the accuracy or reliability of any such statements.
No information given in this Publication should be construed as an endorsement of any particular security, company, or industry, offer, recommendation, or solicitation to purchase or dispose of any securities/financial instruments/products or to enter into any transaction or adopt any hedging, trading or investment strategy. The data/information contained in the Publication is not designed to initiate or conclude any transaction. Neither this Publication nor anything contained herein shall form the basis of any contract or commitment whatsoever. Distribution of this Publication does not oblige CFC to enter into any transaction.
The Publication should not be considered legal, regulatory, credit, tax, or accounting advice. Anyone proposing to rely on or use the information contained in the Publication should independently verify and check its accuracy, completeness, reliability, and suitability and obtain independent professional advice. The Publication does not take into account the investment objectives, financial situations, and specific needs of recipients. The recipient of this Publication must make independent decisions regarding whether this communication and any securities or financial instruments mentioned herein are appropriate in the light of their investment objectives, investment experience, financial situation, existing portfolio holdings and/or investment needs. Recipients will need to decide on their own as to whether or not the contents of this Publication are suitable for them.
Information contained in this Publication is based on various sources, including but not limited to public information, annual reports, and statistical data that CFC believes to be reliable. However, CFC makes no representation or warranty as to the accuracy or completeness of any report or statistical data made in or in connection with this Publication and accepts no responsibility whatsoever for any loss or damage caused by any act or omission taken as a result of the information contained in this Publication. In addition, the names used to describe various financial products or instruments in this Publication may vary from the ones used on different trading platforms.
All views expressed in all reports, analysis and documents are subject to change without notice. CFC may have issued other reports, analysis, or other documents expressing different views from this Publication. In addition, staff members/employees of CFC may provide/present oral or written market commentary or analysis to you that reflect opinions contrary to the opinions expressed in this research and may contain insights and reports inconsistent with the views expressed in this Publication. Neither CFC nor any of its affiliates, group companies, directors, employees, agents, or representatives assume any liability, nor shall they be made liable for any damages, whether direct, indirect, special, or consequential, including loss of revenue or profits that may arise from or in connection with the use of the information provided in this Publication.
Information or data provided by means in this Publication may have many inherent limitations, like module errors or lack of accuracy in its historical data. In addition, data included in the Publication may rely on models that do not reflect or consider all potentially significant factors such as market risk, liquidity risk, interest risk, credit risk etc.
CFC and its affiliates reserve the right to act upon or use the contents hereof at any time. The use of our information, products and services should be on your own due diligence and you agree that CFC is not liable for any failure to achieve the desired return on investment that is in any manner related to availing of services or products of CFC and use of our information, products and services. You acknowledge and agree that past investment performance is not indicative of the future performance results of any investment and that the information contained in this Publication is not to be used as an indication for the future performance of any investment activity. Any prices provided in this Publication are indicative only and do not represent firm quotes as to either price or size.
This Publication is being furnished to you solely for your information and neither it nor any part of it may be used, forwarded, disclosed, distributed or delivered to anyone else. You may not copy, reproduce, display, modify or create derivative works from any data or information contained in this Publication. This document may not be published, circulated, reproduced, or distributed in whole or part to any other person (whether within or in a jurisdiction outside UAE) without the prior written consent of CFC.
Declaration of the Financial Analyst: The Analyst(s) who prepared this report certifies that the opinions contained herein exclusively reflect his or her views. The Analyst further undertakes that he or she has taken reasonable care to maintain independence and objectivity in respect of the opinions herein. The Analyst(s) who wrote this report does not hold securities in the Company mentioned in the report (“Company”). The Analyst(s) confirms that he or she and his / her Associates do not serve as directors or officers of the Company, and the Company or other third parties have not provided or agreed to provide any compensation or other benefits to the Analyst(s) in connection with this report. An “Associate” is defined as the spouse, parent or step-parent, or any minor child (natural or adopted) or minor step-child of the Analyst. The Analyst(s) receives a fixed compensation from CFC. No part of his or her compensation was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this report. The business solicitation or marketing departments of CFC are separate and independent from the reporting line of the Analyst(s).
Trading in financial products carries risk. Trading in leveraged Over-The-Counter (OTC) Derivative products including Contracts for Difference (CFDs) and spot foreign exchange contracts involves a significant risk of loss which can exceed deposits and may not be suitable for all investors. OTC Derivative products / CFDs are complex financial instruments that do not confer any claim or right to the underlying financial instrument. Transactions in these instruments are very risky, and you should trade only with the capital you can afford to lose. Before deciding to trade on these products, you should consider your investment objectives, risk tolerance, and your level of experience. Accordingly, you should ensure that you understand the risks involved and seek independent advice from professionals, if necessary.
Regulated by SCA
Century Financial Consultancy LLC
Reach us:
-
Dubai
6th Floor, Emaar Square Building 4,
Downtown, Dubai, P.O. Box 65777,
Dubai, United Arab Emirates -
Abu Dhabi
27th Floor, Office 2701,
Shining Towers, Abu Dhabi, UAE - +971 (4) 356 2800
- info@century.ae
Disclaimer: Trading in financial products carries risk. Trading in leveraged Over-The-Counter (OTC) Derivative products (including Contracts for Difference (CFDs) and spot foreign exchange contracts) involves a significant risk of loss which can exceed deposits and may not be suitable for all investors. OTC Derivative products / CFDs are complex financial instruments that do not confer any claim or right to the underlying financial instrument. Transactions in these instruments are very risky, and you should trade only with the capital you can afford to lose. Before deciding to trade on these products, you should consider your investment objectives, risk tolerance and your level of experience. Accordingly, you should ensure that you understand the risks involved and seek independent advice from professionals, if necessary.
Century Financial Consultancy LLC (CFC) is duly licensed and regulated by the Securities and Commodities Authority of UAE (SCA) under license numbers 20200000028 and, 301044 to practice the activities of Trading broker in the international markets, Trading broker of the OTC derivatives and currencies in the spot market, Introduction, Financial Consultation and Financial Analysis, and Promotion. CFC is a Limited Liability Company incorporated under the laws of UAE and registered with the Department of Economic Development of Dubai (registration number 768189). CFC has its registered office at 601, Level 6, Building no. 4, Emaar Square, Downtown, Dubai, UAE, PO Box 65777.
Any content available on our website is presented solely to provide information and educate visitors. Under no circumstances is any of this content meant to be construed as an offer, recommendation, advice, or solicitation to buy or sell securities or other financial products.
This website's information is not intended for use by anybody residing outside UAE or where such use would violate local laws or regulations.
